STOCK TITAN

[SCHEDULE 13D/A] Alzamend Neuro, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13D/A

Alzamend Neuro (ALZN) filed Amendment No. 10 to Schedule 13D, updating beneficial ownership by Milton C. Ault III and affiliated entities. The filing is based on 3,539,861 shares outstanding as of October 2, 2025.

Mr. Ault may be deemed to beneficially own 306,321 shares, or approximately 8.0% of the class, including direct holdings and shares attributable through affiliates. Hyperscale Data, Inc. reports 293,349 shares (approximately 7.7%), and Ault Lending, LLC reports 293,337 shares (approximately 7.7%). These positions include 261,743 shares underlying Series B Convertible Preferred Stock and 23,334 shares underlying currently exercisable warrants held by Ault Lending, plus smaller direct common holdings across affiliates.

The filing details voting and dispositive powers across entities and notes that no transactions in the past 60 days occurred other than those listed in an exhibit.

Alzamend Neuro (ALZN) ha depositato la Emendamento n. 10 al Schedule 13D, aggiornando la proprietà beneficiaria di Milton C. Ault III e delle entità affiliate. Il deposito si basa su 3.539.861 azioni in circolazione al 2 ottobre 2025.

Il signor Ault potrebbe essere ritenuto possessore beneficiario di 306.321 azioni, ovvero circa l'8,0% della classe, includendo detenzioni dirette e azioni attribuibili tramite affiliati. Hyperscale Data, Inc. riporta 293.349 azioni (circa 7,7%), e Ault Lending, LLC riporta 293.337 azioni (circa 7,7%). Queste posizioni includono 261.743 azioni sottostanti alle azioni privilegiate convertibili di Serie B e 23.334 azioni sottostanti a warrant attualmente esercitabili detenute da Ault Lending, oltre a piccole posizioni dirette in azioni ordinarie tra le affiliate.

Il deposito dettaglia i poteri di voto e di disposizione tra le entità e osserva che non si sono verificate transazioni negli ultimi 60 giorni diverse da quelle elencate in un allegato.

Alzamend Neuro (ALZN) presentó la Enmienda No. 10 al Schedule 13D, actualizando la titularidad beneficiosa de Milton C. Ault III y entidades afiliadas. El registro se basa en 3,539,861 acciones en circulación al 2 de octubre de 2025.

El Sr. Ault puede considerarse que posee beneficiosamente 306,321 acciones, o aproximadamente el 8,0% de la clase, incluidas participaciones directas y acciones atribuibles a través de afiliadas. Hyperscale Data, Inc. reporta 293,349 acciones (aprox. 7,7%), y Ault Lending, LLC reporta 293,337 acciones (aprox. 7,7%). Estas posiciones incluyen 261,743 acciones subyacentes a las acciones preferentes convertibles de Serie B y 23,334 acciones subyacentes a warrants actualmente exercibles poseídos por Ault Lending, además de menores participaciones directas de acciones comunes entre afiliados.

El registro detalla poderes de voto y dispositivos a través de entidades y señala que no se han producido transacciones en los últimos 60 días, aparte de las enumeradas en un anexo.

Alzamend Neuro (ALZN) 은 Schedule 13D에 대한 Amendment No. 10을 제출하여 Milton C. Ault III 및 관련 기관의 실질 지배를 업데이트했습니다. 제출은 2025년 10월 2일 기준 발행 주식 수 3,539,861주에 기반합니다.

Ault 씨는 유리한 소유권을 306,321주로 간주될 수 있으며, 이는 직접 보유 및 계열 회사를 통해 귀속되는 주식을 포함한 클래스의 약 8.0%에 해당합니다. Hyperscale Data, Inc.293,349주를 보고하며 (약 7.7%), Ault Lending, LLC293,337주를 보고합니다 (약 7.7%). 이러한 포지션에는 시리즈 B 전환우선주에 따른 기초 주식 261,743주현재 행사 가능한 워런트의 기초 주식 23,334주가 포함되며, 이는 Ault Lending이 보유한 것과 더불어 계열사 간의 소액의 직접 일반주 보유를 포함합니다.

제출서는 계열사 전반에 걸친 의결 및 처분 권한을 자세히 설명하고, 지난 60일 동안의 거래는 없다고 밝히며, 이는 부록에 열거된 거래를 제외합니다.

Alzamend Neuro (ALZN) a déposé l’Avenant n° 10 au Schedule 13D, mettant à jour la propriété bénéficiaire de Milton C. Ault III et des entités affiliées. Le dépôt est basé sur 3 539 861 actions en circulation au 2 octobre 2025.

M. Ault peut être réputé détenir de manière bénéficiaire 306 321 actions, soit environ 8,0% de la catégorie, incluant les détentions directes et les actions attribuables par le biais des affiliés. Hyperscale Data, Inc. signale 293 349 actions (environ 7,7%), et Ault Lending, LLC signale 293 337 actions (environ 7,7%). Ces positions incluent 261 743 actions sous-jacentes aux actions privilégiées convertibles de série B et 23 334 actions sous-jacentes à des warrants actuellement exercables détenues par Ault Lending, en plus de petites positions directes en actions ordinaires parmi les affiliés.

Le dépôt détaille les pouvoirs de vote et de distribution entre les entités et note qu’aucune transaction au cours des 60 derniers jours n’a eu lieu, hormis celles répertoriées dans une annexe.

Alzamend Neuro (ALZN) hat Amendment Nr. 10 zum Schedule 13D eingereicht, wodurch die Beneficial Ownership von Milton C. Ault III und verbundenen Einheiten aktualisiert wird. Die Einreichung basiert auf 3.539.861 ausstehende Aktien zum 2. Oktober 2025.

Herr Ault könnte als wirtschaftlich berechtigter Eigentümer von 306.321 Aktien angesehen werden, oder ca. 8,0% der Klasse, einschließlich direkter Bestände und Aktien, die affiliierten Entitäten zugeordnet sind. Hyperscale Data, Inc. meldet 293.349 Aktien (ca. 7,7%), und Ault Lending, LLC meldet 293.337 Aktien (ca. 7,7%). Diese Positionen umfassen 261.743 Aktien unterliegendes Series B wandelbares Vorzugsaktien und 23.334 Aktien unterliegend zu aktuell ausübbaren Warrants gehalten von Ault Lending, plus kleinere direkte Stammaktienbestände über Affiliates.

Die Einreichung beschreibt Stimm- und dispositive Befugnisse über die Einheiten hinweg und stellt fest, dass in den letzten 60 Tagen keine Transaktionen stattgefunden haben, außer denen in einem Anhang aufgeführt.

ألفزا مِند نورو (ALZN) قد قدّمت التعديل رقم 10 على الجدول 13D، محدثًا الملكية المفيدة لميلتون سي. أولت الثالث والكيانات المرتبطة. يعتمد التقديم على 3,539,861 سهمًا قائمة كما في 2 أكتوبر 2025.

قد يعتبر السيد أولت مالكاً بشكل مفيد 306,321 سهمًا، أو حوالي 8.0٪ من الفئة، بما في ذلك الحيازات المباشرة والأسهم المنسوبة من خلال الشركات التابعة. Hyperscale Data, Inc. تبلغ عن 293,349 سهمًا (حوالي 7.7%)، وAult Lending, LLC تبلغ عن 293,337 سهمًا (حوالي 7.7%). هذه المواقع تشمل 261,743 سهمًا مبدئية مرتبطة بأسهم ممتازة قابلة للتحويل من الفئة B و23,334 سهمًا مرتبطة بالوَرْنْتات القابلة حاليا exercised التي يمتلكها Ault Lending، إضافة إلى حيازات الأسهم العادية المباشرة أصغر عبر الشركات التابعة.

تفصل الوثيقة صلاحيات التصويت والإدارة عبر الكيانات وتلاحظ أنه لم تحدث أي معاملات خلال آخر 60 يومًا غير تلك المذكورة في الملحق.

Alzamend Neuro (ALZN) 已提交对 Schedule 13D 的 Amendment No. 10,更新 Milton C. Ault III 及其关联实体的实益所有权。该申报基于截至 2025 年 10 月 2 日的 在外流通股 3,539,861 股

Ault 先生可能被认定为实益拥有 306,321 股,或该集团约 8.0% 的股份,包括直接持有和通过关联公司归属的股份。Hyperscale Data, Inc. 报告 293,349 股约 7.7%),而 Ault Lending, LLC 报告 293,337 股约 7.7%)。这些头寸包括 261,743 股属于系列 B 可转换优先股的基础股份以及 23,334 股属于目前可行使的认股权证,由 Ault Lending 持有,加上关联方的较小直接普通股头寸。

申报详细列出跨实体的投票和处置权,并指出在过去 60 天内除了附表中列出的交易外,未发生任何交易。

Positive
  • None.
Negative
  • None.

Insights

Ownership update shows Ault-related entities at ~8% of ALZN.

The amendment reports consolidated beneficial ownership tied to Milton C. Ault III and affiliates, anchored to October 2, 2025 outstanding shares. The positions blend direct common shares with derivative securities, including Series B Convertible Preferred Stock and currently exercisable warrants.

Concentration near the 5% reporting threshold is already exceeded, with Mr. Ault at 8.0% and key affiliates at 7.7%. Voting and dispositive power is split between sole and shared, reflecting holdings across entities.

Actual market impact depends on holder decisions and any conversions or exercises permitted by the instruments. Subsequent filings may provide updated ownership if positions change or derivatives are exercised.

Alzamend Neuro (ALZN) ha depositato la Emendamento n. 10 al Schedule 13D, aggiornando la proprietà beneficiaria di Milton C. Ault III e delle entità affiliate. Il deposito si basa su 3.539.861 azioni in circolazione al 2 ottobre 2025.

Il signor Ault potrebbe essere ritenuto possessore beneficiario di 306.321 azioni, ovvero circa l'8,0% della classe, includendo detenzioni dirette e azioni attribuibili tramite affiliati. Hyperscale Data, Inc. riporta 293.349 azioni (circa 7,7%), e Ault Lending, LLC riporta 293.337 azioni (circa 7,7%). Queste posizioni includono 261.743 azioni sottostanti alle azioni privilegiate convertibili di Serie B e 23.334 azioni sottostanti a warrant attualmente esercitabili detenute da Ault Lending, oltre a piccole posizioni dirette in azioni ordinarie tra le affiliate.

Il deposito dettaglia i poteri di voto e di disposizione tra le entità e osserva che non si sono verificate transazioni negli ultimi 60 giorni diverse da quelle elencate in un allegato.

Alzamend Neuro (ALZN) presentó la Enmienda No. 10 al Schedule 13D, actualizando la titularidad beneficiosa de Milton C. Ault III y entidades afiliadas. El registro se basa en 3,539,861 acciones en circulación al 2 de octubre de 2025.

El Sr. Ault puede considerarse que posee beneficiosamente 306,321 acciones, o aproximadamente el 8,0% de la clase, incluidas participaciones directas y acciones atribuibles a través de afiliadas. Hyperscale Data, Inc. reporta 293,349 acciones (aprox. 7,7%), y Ault Lending, LLC reporta 293,337 acciones (aprox. 7,7%). Estas posiciones incluyen 261,743 acciones subyacentes a las acciones preferentes convertibles de Serie B y 23,334 acciones subyacentes a warrants actualmente exercibles poseídos por Ault Lending, además de menores participaciones directas de acciones comunes entre afiliados.

El registro detalla poderes de voto y dispositivos a través de entidades y señala que no se han producido transacciones en los últimos 60 días, aparte de las enumeradas en un anexo.

Alzamend Neuro (ALZN) 은 Schedule 13D에 대한 Amendment No. 10을 제출하여 Milton C. Ault III 및 관련 기관의 실질 지배를 업데이트했습니다. 제출은 2025년 10월 2일 기준 발행 주식 수 3,539,861주에 기반합니다.

Ault 씨는 유리한 소유권을 306,321주로 간주될 수 있으며, 이는 직접 보유 및 계열 회사를 통해 귀속되는 주식을 포함한 클래스의 약 8.0%에 해당합니다. Hyperscale Data, Inc.293,349주를 보고하며 (약 7.7%), Ault Lending, LLC293,337주를 보고합니다 (약 7.7%). 이러한 포지션에는 시리즈 B 전환우선주에 따른 기초 주식 261,743주현재 행사 가능한 워런트의 기초 주식 23,334주가 포함되며, 이는 Ault Lending이 보유한 것과 더불어 계열사 간의 소액의 직접 일반주 보유를 포함합니다.

제출서는 계열사 전반에 걸친 의결 및 처분 권한을 자세히 설명하고, 지난 60일 동안의 거래는 없다고 밝히며, 이는 부록에 열거된 거래를 제외합니다.

Alzamend Neuro (ALZN) a déposé l’Avenant n° 10 au Schedule 13D, mettant à jour la propriété bénéficiaire de Milton C. Ault III et des entités affiliées. Le dépôt est basé sur 3 539 861 actions en circulation au 2 octobre 2025.

M. Ault peut être réputé détenir de manière bénéficiaire 306 321 actions, soit environ 8,0% de la catégorie, incluant les détentions directes et les actions attribuables par le biais des affiliés. Hyperscale Data, Inc. signale 293 349 actions (environ 7,7%), et Ault Lending, LLC signale 293 337 actions (environ 7,7%). Ces positions incluent 261 743 actions sous-jacentes aux actions privilégiées convertibles de série B et 23 334 actions sous-jacentes à des warrants actuellement exercables détenues par Ault Lending, en plus de petites positions directes en actions ordinaires parmi les affiliés.

Le dépôt détaille les pouvoirs de vote et de distribution entre les entités et note qu’aucune transaction au cours des 60 derniers jours n’a eu lieu, hormis celles répertoriées dans une annexe.

Alzamend Neuro (ALZN) hat Amendment Nr. 10 zum Schedule 13D eingereicht, wodurch die Beneficial Ownership von Milton C. Ault III und verbundenen Einheiten aktualisiert wird. Die Einreichung basiert auf 3.539.861 ausstehende Aktien zum 2. Oktober 2025.

Herr Ault könnte als wirtschaftlich berechtigter Eigentümer von 306.321 Aktien angesehen werden, oder ca. 8,0% der Klasse, einschließlich direkter Bestände und Aktien, die affiliierten Entitäten zugeordnet sind. Hyperscale Data, Inc. meldet 293.349 Aktien (ca. 7,7%), und Ault Lending, LLC meldet 293.337 Aktien (ca. 7,7%). Diese Positionen umfassen 261.743 Aktien unterliegendes Series B wandelbares Vorzugsaktien und 23.334 Aktien unterliegend zu aktuell ausübbaren Warrants gehalten von Ault Lending, plus kleinere direkte Stammaktienbestände über Affiliates.

Die Einreichung beschreibt Stimm- und dispositive Befugnisse über die Einheiten hinweg und stellt fest, dass in den letzten 60 Tagen keine Transaktionen stattgefunden haben, außer denen in einem Anhang aufgeführt.






If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






SCHEDULE 13D




Comment for Type of Reporting Person:
Sole voting and dispositive power represents shares of Common Stock. Shared voting and dispositive power represents (i) 261,743 shares of Common Stock underlying shares of Series B Convertible Preferred Stock held by Ault Lending, LLC, (ii) 23,334 shares of Common Stock underlying currently exercisable warrants held by Ault Lending, LLC, (iii) 8,260 shares of Common Stock held by Ault Lending, LLC, (iv) 11,068 shares of Common Stock held by Ault Life Sciences, Inc., (v) 61 shares of Common Stock held by Ault Life Sciences Fund, LLC, and (vi) 12 shares of Common Stock underlying currently exercisable warrants held by Hyperscale Data, Inc.


SCHEDULE 13D




Comment for Type of Reporting Person:
Represents (i) 3,333 shares of Common Stock and (ii) 185 shares of Common Stock underlying stock options currently exercisable or exercisable within 60 days.


SCHEDULE 13D




Comment for Type of Reporting Person:
Represents shares of Common Stock underlying stock options currently exercisable or exercisable within 60 days.


SCHEDULE 13D




Comment for Type of Reporting Person:
Represents shares of Common Stock underlying stock options currently exercisable or exercisable within 60 days.


SCHEDULE 13D




Comment for Type of Reporting Person:
Represents (i) 615 shares of Common Stock and (ii) 1,111 shares of Common Stock underlying stock options currently exercisable or exercisable within 60 days.


SCHEDULE 13D




Comment for Type of Reporting Person:
Represents (i) 12 shares of Common Stock underlying currently exercisable warrants held by it, (ii) 261,743 shares of Common Stock underlying shares of Series B Convertible Preferred Stock held by Ault Lending, LLC, (iii) 23,334 shares of Common Stock underlying currently exercisable warrants held by Ault Lending, LLC, and (iv) 8,260 shares of Common Stock held by Ault Lending, LLC.


SCHEDULE 13D




Comment for Type of Reporting Person:
Represents (i) 8,260 shares of Common Stock, (ii) 261,743 shares of Common Stock underlying shares of Series B Convertible Preferred Stock and (iii) 23,334 shares of Common Stock underlying currently exercisable warrants.


SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D


MILTON C. AULT, III
Signature:/s/ Milton C. Ault, III
Name/Title:Individual
Date:10/03/2025
WILLIAM B. HORNE
Signature:/s/ William B. Horne
Name/Title:Individual
Date:10/03/2025
HENRY C.W. NISSER
Signature:/s/ Henry C. Nisser
Name/Title:Individual
Date:10/03/2025
KENNETH S. CRAGUN
Signature:/s/ Kenneth S. Cragun
Name/Title:Individual
Date:10/03/2025
DAVID J. KATZOFF
Signature:/s/ David J. Katzoff
Name/Title:Individual
Date:10/03/2025
HYPERSCALE DATA, INC.
Signature:/s/ Milton C. Ault, III
Name/Title:Executive Chairman
Date:10/03/2025
AULT LENDING, LLC
Signature:/s/ David J. Katzoff
Name/Title:Manager
Date:10/03/2025
AULT LIFE SCIENCES, INC.
Signature:/s/ Milton C. Ault, III
Name/Title:Chief Executive Officer
Date:10/03/2025
AULT LIFE SCIENCES FUND, LLC
Signature:/s/ Milton C. Ault, III
Name/Title:Managing Member
Date:10/03/2025

FAQ

What stake in ALZN does Milton C. Ault III report in this 13D/A?

He may be deemed to beneficially own 306,321 shares, or approximately 8.0% of Alzamend Neuro’s common stock.

How many ALZN shares were outstanding for the ownership calculations?

The filing uses 3,539,861 shares outstanding as of October 2, 2025.

What do Hyperscale Data and Ault Lending report owning in ALZN?

Hyperscale Data reports 293,349 shares (~7.7%); Ault Lending reports 293,337 shares (~7.7%).

Which derivative securities are included in the reported ALZN ownership?

Holdings include 261,743 shares underlying Series B Convertible Preferred Stock and 23,334 shares underlying currently exercisable warrants held by Ault Lending.

Did the reporting persons trade ALZN in the last 60 days?

They state no transactions in the past 60 days except as set forth in Exhibit 1.

Who else is listed and what are their ALZN stakes?

William B. Horne: 3,518 shares (~0.1%); Henry C.W. Nisser: 926 shares; Kenneth S. Cragun: 1,111 shares; David J. Katzoff: 1,726 shares.
Alzamend Neuro Inc

NASDAQ:ALZN

ALZN Rankings

ALZN Latest News

ALZN Latest SEC Filings

ALZN Stock Data

8.82M
3.72M
0.81%
0.07%
4.37%
Biotechnology
Pharmaceutical Preparations
Link
United States
ATLANTA